Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(-)-MK 801 maleate
Description: NMDA antagonist; less active enantiomer of (+)-MK 801
Chemical Name: (5R,10S)-(-)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cylcohepten-5,10-imine maleate
Purity: ≥99% (HPLC)
Biological Activity for (-)-MK 801 maleate
(-)-MK 801 maleate is a less active enantiomer (10-fold less potent in behavioral studies) than (+)-MK 801 maleate.
(+)-enantiomer also available.
Compound Libraries for (-)-MK 801 maleate
(-)-MK 801 maleate is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
Technical Data for (-)-MK 801 maleate
| M. Wt | 337.37 |
| Formula | C16H15N.C4H4O4 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 121917-57-5 |
| PubChem ID | 16219612 |
| InChI Key | QLTXKCWMEZIHBJ-FWHYOZOBSA-N |
| Smiles | O=C(O)/C=C\C(O)=O.C[C@@]14C3=C(C=CC=C3)C[C@H](N4)C2=C1C=CC=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (-)-MK 801 maleate
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 8.43 | 25 with gentle warming | |
| DMSO | 33.74 | 100 |
Preparing Stock Solutions for (-)-MK 801 maleate
The following data is based on the product molecular weight 337.37. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.96 mL | 14.82 mL | 29.64 mL |
| 5 mM | 0.59 mL | 2.96 mL | 5.93 mL |
| 10 mM | 0.3 mL | 1.48 mL | 2.96 mL |
| 50 mM | 0.06 mL | 0.3 mL | 0.59 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for (-)-MK 801 maleate
References for (-)-MK 801 maleate
References are publications that support the biological activity of the product.
Genovese and Lu (1991) Effects of MK-801 stereoisomers on schedule-controlled behavior in rats. Psychopharmacology. 105 477 PMID: 1771215
Thompson et al (1990) Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-MthD.-aspartate antagonists. J.Med.Chem. 33 789 PMID: 1688947
If you know of a relevant reference for (-)-MK 801 maleate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (-)-MK 801 maleate, (-)-MK 801 maleate supplier, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, (-)-MK801, maleate, MK801, 0955, Tocris Bioscience
3 Citations for (-)-MK 801 maleate
Citations are publications that use Tocris products. Selected citations for (-)-MK 801 maleate include:
Yang et al (2005) Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake. J Pharmacol Exp Ther 25 4288 PMID: 15858055
Huang et al (2004) Astrocyte glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of hippocampal interneurons. J Neurosci 24 4551 PMID: 15140926
Huang et al (2007) Actin polymerization and ERK phosphorylation are required for Arc/Arg3.1 mRNA targeting to activated synaptic sites on dendrites. J Neurosci 27 9054 PMID: 17715342
Do you know of a great paper that uses (-)-MK 801 maleate from Tocris? Please let us know.
Reviews for (-)-MK 801 maleate
There are currently no reviews for this product. Be the first to review (-)-MK 801 maleate and earn rewards!
Have you used (-)-MK 801 maleate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Huntington's Disease Research Product Guide
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
- Somatic Instability
- Proteolysis and Inclusion Bodies
- Transcriptional Dysregulation
- Mitochondrial Dysfunction
- Nuclear-Cytoplasmic Transport Interference
- Excitotoxicity
- Stem Cells
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.